DOCSLIB.ORG

( 12 ) Patent Application Publication ( 10 ) Pub . No .: US 2020/0121788 A1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
( 12 ) Patent Application Publication ( 10 ) Pub . No .: US 2020/0121788 A1 US 20200121788A1 IN (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No .: US 2020/0121788 A1 MASSIMINI et al. (43 ) Pub . Date : Apr. 23 , 2020 ( 54 ) ABITUZUMAB FOR THE TREATMENT OF A61K 31/44 (2006.01 ) COLORECTAL CANCER A61P 35/00 (2006.01 ) (52 ) U.S. Cl. ( 71) Applicant: Merck Patent GmbH , Darmstadt (DE ) CPC ... A61K 39/39558 (2013.01 ) ; CO7K 16/2848 ( 2013.01 ) ; CO7K 16/2863 ( 2013.01 ) ; CO7K ( 72 ) Inventors: Giorgio MASSIMINI, Darmstadt (DE ) ; 16/22 (2013.01 ) ; A61K 31/4745 ( 2013.01 ) ; Ilhan Celik , Zwingenberg (DE ) ; Josef A61K 31/513 ( 2013.01 ) ; A61K 2039/505 Straub , Seeheim - Jugenheim (DE ) ; Rolf ( 2013.01) ; A61K 31/519 ( 2013.01 ) ; A61K Bruns, Darmstadt ( DE ) 33/243 (2019.01 ) ; A6IK 38/179 ( 2013.01) ; A61K 31/44 ( 2013.01) ; A61P 35/00 ( 2018.01 ) ; ( 73 ) Assignee: Merck Patent GmbH , Darmstadt (DE ) CO7K 2317/76 ( 2013.01) ; A61K 31/7072 ( 21 ) Appl. No .: 16 /657,828 ( 2013.01) ( 22 ) Filed : Oct. 18 , 2019 (57 ) ABSTRACT Methods of treatment of colorectal cancer can include the Related U.S. Application Data administration of the anti - alpha - v integrin (receptor ) anti (60 ) Provisional application No. 62 / 748,114 , filed on Oct. body Abituzumab . Preferably , the methods of treating col 19 , 2018 . orectal cancer can include treating Stage II - IV colorectal cancer, metastatic colorectal cancer , left - sided colorectal Publication Classification cancer and /or left- sided metastatic colorectal cancer, involv ( 51) Int. Ci. ing the administration of said Abituzumab to patients in need A61K 39/395 ( 2006.01 ) thereof. Abituzumab is also useful for the manufacture of a COZK 16/28 ( 2006.01 ) medicament for treating colorectal cancer , preferably col COOK 16/22 ( 2006.01 ) orectal cancer as defined herein . Abituzumab is further A61K 31/4745 ( 2006.01 ) useful for the manufacture of a medicament for treating A61K 31/513 ( 2006.01 ) colorectal cancer in combination with suitable targeted A61K 31/7072 ( 2006.01) therapy concepts , such as growth factor or growth factor A61K 31/519 ( 2006.01) receptor targeting monoclonal antibodies , and / or chemo A61K 33/243 ( 2006.01 ) therapy . A61K 38/17 ( 2006.01 ) Specification includes a Sequence Listing . mo 20 Submucosa Patent Application Publication Apr. 23, 2020 Sheet 1 of 11 US 2020/0121788 A1 ROAD IT!!! Subset Fig . 1 Patent Application Publication Apr. 23, 2020 Sheet 2 of 11 US 2020/0121788 A1 M 3 ** Fig . 2 Fig . 3 Patent Application Publication Apr. 23, 2020 Sheet 3 of 11 US 2020/0121788 A1 Randomized phase il part 5338 Abluzumab 1,000 mg every 2 weeks + Soc 2 Fig . 4 Patent Application Publication Apr. 23, 2020 Sheet 4 of 11 US 2020/0121788 A1 KHASiruan in : 3 ) Randorismo ( 26) located to abituzumal 500173 Allocated to returnabinoiochi cocinab u vinoteoan ( 73 ) Donec accated interverter Donceive allocated * Did not receive allocied Intervention ( 2 ) Lost to folk - p19isy Los tonowa ini ) Discontinued intervention 107 Disexso progresa33 - Disease progress (0-10 ) -Deprogression ( 2 ) Adverse event marceptabi koly attem Muldew but Survival data . - Dia.costante iuxcity without -Utacceptable toxicity without cose reochon ( 2 ) Analysedior ITpoulation ( +33 Bigios to virstwe surgery: ... 17 ( 2 Analysed in ITT Beniculation ( 332 Fig . 5 Patent Application Publication Apr. 23, 2020 Sheet 5 of 11 US 2020/0121788 A1 A Abituzumab 500 mg ?? *** per ?? Fig . 6A Patent Application Publication Apr. 23, 2020 Sheet 6 of 11 US 2020/0121788 A1 Suzumab 500 mg Pionsbilityofsurvival 3 2 goan 7 tuzumab 1000 rg 7 : ?? Fig . 6B Patent Application Publication Apr. 23, 2020 Sheet 7 of 11 US 2020/0121788 A1 20 Fig . 7 Patent Application Publication Apr. 23, 2020 Sheet 8 of 11 US 2020/0121788 A1 wwwwwwwww wwwwwww -- nie Fig . 8 Patent Application Publication Apr. 23, 2020 Sheet 9 of 11 US 2020/0121788 A1 Abituzzo 500 YO (KROSS 185 % C1030-100 ] .. yummm 5 1 *** Jonas moment Fig . 9 Patent Application Publication Apr. 23 , 2020 Sheet 10 of 11 US 2020/0121788 A1 ? 0 017 06 34 0 3 3 23 27 Overal survival (months ) 25AN . Atidex120 1080p Fig . 10A Patent Application Publication Apr. 23 , 2020 Sheet 11 of 11 US 2020/0121788 A1 3 0 my X 3 Fig . 10B US 2020/0121788 Al Apr. 23, 2020 1 ABITUZUMAB FOR THE TREATMENT OF [0006 ] In both cancer of the colon and rectum , chemo COLORECTAL CANCER therapy may be used in addition to surgery in certain cases . In rectal cancer , chemotherapy may be used in the neoad CROSS - REFERENCE TO RELATED juvant setting. APPLICATIONS [0007 ] If cancer has entered the lymph nodes , adding the chemotherapy agents fluorouracil or capecitabine increases [0001 ] The present application claims the benefit to the life expectancy. If the lymph nodes do not contain cancer , provisional application 62 / 748,114 , filed on Oct. 19 , 2018 , the benefits of chemotherapy are controversial. If the cancer which is incorporated by reference in its entirety . is widely metastatic or unresectable , up to now , treatment is mainly palliative . Typically in this setting , a number of REFERENCE TO A SEQUENCE LISTING different chemotherapy medications may be used . Chemo therapy drugs for this condition may include capecitabine , [0002 ] The present application incorporates by reference fluorouracil, irinotecan , leucovorin , oxaliplatin and UFT . the material in the ASCII text file “ 2019-10-07 - P18-218_ Preferably , fluorouracil may be administered as its Prodrugs , ST25.txt ,” created on Oct. 7 , 2019 , having a size of 7878 such as Capecitabine and / or 5 -Fluorocytosine . Another type bytes , which is submitted herewith . of agent that is sometimes used are the epidermal growth factor receptor inhibitors . BACKGROUND OF THE INVENTION [0008 ] While a combination of radiation and chemo therapy may be useful for rectal cancer, its use in colon Field of the Invention cancer is not routine due to the sensitivity of the bowels to [0003 ] Methods of treatment of colorectal cancer can radiation . Just as for chemotherapy , radiotherapy can be comprise the administration of the anti- alpha - v integrin used in the neoadjuvant and adjuvant setting for some stages ( receptor ) antibody Abituzumab . Preferably , such methods of rectal cancer. relate to treating colorectal cancer , Stage II - IV colorectal [0009 ] However , the indication colorectal cancer (CRC ) is cancer , metastatic colorectal cancer, left - sided colorectal known and widely understood in the art. Preferably , col cancer and / or left - sided metastatic colorectal comprising the orectal cancer is a heterogeneous indication disease that can administration of said Abituzumab to patients in need preferably be distinguished by characteristics, including , but thereof. More preferably , such methods relate to treating not limited to the location of origin , the kind of tissue colorectal cancer , preferably the above given kinds or stages affected and /or the stage of the disease as it develops. of colorectal cancer , said methods comprising the adminis [0010 ] The staging of colorectal cancer is widely known tration of the anti - alpha - v integrin ( receptor) antibody Abitu and understood in the art . Preferably , the different stages of zumab additionally to an existing treatment or treatment development are divided in four or five categories , prefer regimen for said kinds or stages of colorectal cancer. Thus, ably four categories. The earliest stage colorectal cancers are Abituzumab may be used for the manufacture of a medica preferably categorised “ stage 0 ” ( a very early cancer) , and ment for treating colorectal cancer , preferably colorectal then range from stages I ( 1 ) through IV ( 4 ). As a rule , the cancer as defined herein , and / or Abituzumab for the manu lower the number, the less the cancer has developed , pro facture of a medicament for treating colorectal cancer in gressed and /or spread . A higher number , such as stage IV , combination with suitable targeted therapy concepts , such as preferably means cancer has spread more . And within a growth factor or growth factor receptor targeting monoclo stage , an earlier letter preferably means a lower stage . nal antibodies , and / or chemotherapy . Although each person's cancer experience is unique, cancers with similar stages tend to have a similar outlook and are Discussion of the Background often treated in much the same way. [ 0004 ] Colorectal cancer ( preferably also known as colon [0011 ] The staging system most often used for colorectal cancer , rectal cancer and /or bowel cancer ) is when cancer cancer is the American Joint Committee on Cancer ( AJCC ) develops in the colon or rectum (parts of the large intestine ). TNM system , which is based on 3 key pieces of information : It is due to the abnormal growth of cells that they generally [ 0012 ] The extent (size ) of the tumor ( T ) : How far has have the ability to invade or spread to other parts of the body. the cancer grown into the wall of the colon or rectum ? [ 0005 ] To date , treatments used for colorectal cancer may These layers , from the inner to the outer layers as include some combination of surgery , radiation therapy , shown in FIG . 1 , include : chemotherapy and targeted therapy . Cancers that are con [0013 ] The inner lining (mucosa ), which is the layer fined within the wall of the colon may be curable with surgery while cancer that has spread widely are usually not in which nearly all colorectal cancers start . This curable with management focusing on improving quality of includes a thin muscle layer (muscularis mucosa ) . life and symptoms. Five -year survival rates in the United [0014 ] The fibrous tissue beneath this muscle layer States are around 65 % . This , however , depends on how ( submucosa ) advanced the cancer is , whether or not all the cancer can be [ 0015 ] A thick muscle layer (muscularis propria ) removed with surgery, and the person's overall health . Globally , colorectal cancer is the third most common type of [0016 ] The thin , outermost layers of connective tis cancer making up about 10 % of all cases .
Load more

Recommended publications
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Andrew Lai Thesis
    TOWARDS THE DEVELOPMENT OF NOVEL BISPECIFIC ANTIBODIES TO INHIBIT KEY CELL SURFACE RECEPTORS INTEGRAL FOR THE GROWTH AND MIGRATION OF TUMOUR CELLS Andrew Lai Bachelor of Science, UNSW 2008 Master of Biotechnology, QUT 2010 Bachelor of Applied Science (Hons), QUT 2012 Submitted for the degree of Doctor of Philosophy Institute of Health and Biomedical Innovation Faculty of Health Queensland University of Technology 2016 Keywords Breast cancer, extracellular matrix, insulin-like growth factor, metastasis, migration, therapeutics, phage display, single chain variable fragments, vitronectin Towards the development of novel bispecific antibodies to inhibit key cell surface receptors integral for the growth and migration of tumour cells i Abstract Metastatic breast cancer, or breast cancer which has spread from the primary tumour to distal secondary sites, remains a major killer of women today. Researchers have observed that the relationship between tumour cells and its surrounding environment plays an important role in cancer progression. One such interaction is between the Insulin-like growth factor (IGF) system and the integrin system, which has been demonstrated to be involved in cancer cell metabolic activity and migration. Therefore, the aim of this project was to translate this knowledge into the generation of bispecific antibody fragments (BsAb) targeting both systems, in order to disrupt their roles in cancer growth and metastasis. To screen for IGF-1R and αv integrin binding ScFv, a phage display enrichment procedure using the Tomlinson ScFv libraries was conducted. After the panning cycles, 192 clones were screened for binding using ELISA, of which 16 were selected for sequencing. Analysis of the results revealed 1 IGF-R and 3 αv integrin unique binding ScFv, which were all subsequently expressed in a bacterial expression system.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
    US 20170172932A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub. Date: Jun. 22, 2017 (54) EARLY CANCER DETECTION AND A 6LX 39/395 (2006.01) ENHANCED IMMUNOTHERAPY A61R 4I/00 (2006.01) (52) U.S. Cl. (71) Applicant: Gholam A. Peyman, Sun City, AZ CPC .......... A61K 9/50 (2013.01); A61K 39/39558 (US) (2013.01); A61K 4I/0052 (2013.01); A61 K 48/00 (2013.01); A61K 35/17 (2013.01); A61 K (72) Inventor: sham A. Peyman, Sun City, AZ 35/15 (2013.01); A61K 2035/124 (2013.01) (21) Appl. No.: 15/143,981 (57) ABSTRACT (22) Filed: May 2, 2016 A method of therapy for a tumor or other pathology by administering a combination of thermotherapy and immu Related U.S. Application Data notherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and pre (63) Continuation-in-part of application No. 14/976,321, vents tumor recurrence, either locally or at a different site, by filed on Dec. 21, 2015. boosting the patient’s immune response both at the time or original therapy and/or for later therapy. With respect to Publication Classification gene delivery, the inventive method may be used in cancer (51) Int. Cl. therapy, but is not limited to such use; it will be appreciated A 6LX 9/50 (2006.01) that the inventive method may be used for gene delivery in A6 IK 35/5 (2006.01) general. The controlled and precise application of thermal A6 IK 4.8/00 (2006.01) energy enhances gene transfer to any cell, whether the cell A 6LX 35/7 (2006.01) is a neoplastic cell, a pre-neoplastic cell, or a normal cell.
    [Show full text]
  • Perspektive 2023
    Perspektive 2023 Neue Medikamente in Entwicklung Inhalt 2 Neue Medikamente in Sicht 6 Neue Wege 8 Neue Chancen für Krebspatienten 10 Entzündungen zum Erliegen bringen 13 Infektionen bekämpfen 14 Gegen Krankheiten unterschiedlichster Art 16 Kindermedikamente und Orphan Drugs 19 Medikamente für Männer und Frauen 20 Die neuen Wirkstoffe 23 Der Beitrag Deutschlands 26 Projekte, die bis 2023 zu einer Zulassung führen können 44 Schwerpunkte der vfa-Mitglieder 46 Kontakt Blick voraus Mehr als zehn Jahre dauert es von der Idee bis zur Zulassung, manch- mal mehr als zwanzig. Erfolge mit neuen Medikamenten kann also nur ernten, wer lange vorher gesät hat. Das haben die forschenden Pharma-Unternehmen des vfa in den späten 2000er- und frühen 2010er-Jahren reichlich getan, so dass nun besonders viele Medika- mente in ihrer Erprobung weit fort geschritten sind. Welche es noch vor Ende 2023 bis zu einer Zulassung oder Zulassungserweiterung schaffen könnten, zeigt diese Veröffentlichung. Sie macht deutlich, dass zahlreiche Patientinnen und Patienten gute Aussichten auf bessere Behandlungsmöglich keiten für ihre Leiden haben. vfa – die forschenden Pharma-Unternehmen Perspektive 2023 Neue Medikamente in Sicht Viele Krankheiten sind in den letzten Jahren besser behandelbar geworden, und Patienten und Ärzte hoffen, dass dieser Strom des Fortschritts nicht abreißt. Die Chancen dafür stehen gut. Denn forschende Pharma-Unternehmen entwickeln derzeit gegen mehr als 145 Krankheiten Medikamente, die bis spätestens Ende 2023 die Zulassung erhalten könnten. Das zeigt eine Erhebung des vfa bei seinen Mitgliedsunter nehmen vom Oktober 2019. Demnach könnten bis Ende 2023 insgesamt 434 Sämtliche Projekte, die in der Erhebung erfasst ihrer Projekte zu einer Zulassung oder Zulassungs- wurden, sind ab S.
    [Show full text]
  • London - Westminster Research Ethics Committee
    Research Ethics Service London - Westminster Research Ethics Committee Annual Report 01 April 2016 - 31 March 2017 Part 1 – Committee Membership and Training Name of REC: London - Westminster Research Ethics Committee Type of REC: RECs recognised to review CTIMPS in healthy volunteers - type i, RECs recognised to review CTIMPS in patients - type iii Type of Flag: Phase 1 Studies in Healthy Volunteers Chair: Mr Robert Goldstein Vice-Chair: Mr Michael Puntis Alternate Vice-Chair: No Alternate Vice-Chair appointed at time of report REC Manager: Ms Rachel Katzenellenbogen REC Assistant: Mr Ewan Waters (01/04/2016-06/03/2017) Ms Laila Sarwar (06/03/2017-31/03/2017) Committee Address: 4 Minshull Street Manchester M1 3DZ Telephone: 0207 104 8012 Email: [email protected] London - Westminster Research Ethics Committee Annual Report Page 2 Chair’s overview of the past year: There has been a good level of ethical debate concerning the applications presented to Westminster REC. Members have in most cases demonstrated a good understanding of the issues. The balance of backgrounds and skills of REC members has been such as to allow different viewpoints to be considered. There has been very good support from the REC Manager both administratively and also through guidance on HRA principles and procedures. The Westminster REC has continued to examine a significant number of clinical drug trials which is one if its main areas of expertise. At this stage, Westminster REC has not seen the new prescreening assessments by the HRA of research applications and so cannot comment on their usefulness and effectiveness.
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    INN Working Document 05.179 Update 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2013 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int ) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected] ). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html ). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
    ll ( (51) International Patent Classification: (74) Agent: NETTER, Jr., Robert, C. et al.; Dann, Dorf- C07K 16/28 (2006.01) man, Herrell and Skillman, 1601 Market Street, Suite 2400, Philadelphia, PA 19103-2307 (US). (21) International Application Number: PCT/US2020/030354 (81) Designated States (unless otherwise indicated, for every kind of national protection av ailable) . AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 29 April 2020 (29.04.2020) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (26) Publication Language: English KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (30) Priority Data: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/840,465 30 April 2019 (30.04.2019) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, (71) Applicants: INSTITUTE FOR CANCER RESEARCH TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW. D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER [US/US]; 333 Cottman Av¬ (84) Designated States (unless otherwise indicated, for every enue, Philadelphia, PA 191 11-2497 (US). UNIVERSTIY kind of regional protection available) . ARIPO (BW, GH, OF KANSAS [US/US]; 245 Strong Hall, 1450 Jayhawk GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Boulevard, Lawrence, KS 66045 (US).
    [Show full text]
  • 14-350 Phrma Cancer2014 1001.Indd
    2014 MEDICINES IN DEVELOPMENT REPORT Cancer PRESENTED BY AMERICA’S BIOPHARMACEUTICAL RESEARCH COMPANIES Nearly 800 Medicines and Vaccines in Clinical Testing For Cancer Offer New Hope to Patients In recent decades, great progress has America’s biopharmaceutical companies Medicines in Development for been made in the fi ght against cancer. are responding to the needs of cancer Cancer Advances in molecular and genomic patients, working to develop more and research have unveiled complexities better treatments. Researchers are now Application Submitted and changed the perception of cancer, exploring new high-tech weapons to Phase III which we now know is more than 200 fi ght the disease as well as ways to use Phase II unique diseases. Continued research existing medicines, either alone or in has expanded our knowledge of how combination with other therapies, to Phase I cancer develops and how to target treat various cancers. The 771 medicines 98 medicines for specifi c cancer types, and vaccines are either in clinical trials which has resulted in more effective or awaiting review by the U.S. Food and therapies for patients. Drug Administration (FDA) and include: 87 A cancer diagnosis once meant almost • A monoclonal antibody for colorectal 78 certain death but with new therapies, cancer that targets a cell surface 73 better testing, earlier diagnosis and protein that plays a role in tumor follow-up care, patients are often able growth and metastases; to live longer with a better quality of life. According to the American Cancer 56 Contents Society (ACS), the number of cancer Medicines and Vaccines in 48 survivors living in the United States has Development to Treat Cancer ...............2 increased from 3 million in 1971 to 13.7 Advances in Cancer Treatment .............3 million in 2012.
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) FORMER DOCUMENT NUMBER: INN Working Document 05.179 © World Health Organization 2019 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]